Table 1 Clinical features of the 569 patients registered in the ORA and included in the present study
Abatacept monotherapy (n = 188) | Abatacept + DMARDs (n = 381) | |
|---|---|---|
Sex, female n (%) | 153 (81 %) | 297 (78 %) |
Age, median (range) | 63 (22–89) | 59 (23–89) |
Duration of disease, median (range) | 16 (3–51) | 14 (2–45) |
Inclusion DAS-28 score, median (range) | 5.5 (2–8.9) | 5.3 (1.6–8.5) |
Previous anti-TNF therapy, n (%) | ||
0 | 26 (14 %) | 38 (10 %) |
1 | 47 (25 %) | 85 (22 %) |
2 | 72 (38 %) | 156 (41 %) |
3 | 43 (23 %) | 102 (27 %) |
Previous rituximab therapy, n (%) | 72 (38 %) | 104 (27 %) |
Cortisone treatment, n (%) | 144 (75 %) | 280 (73 %) |
Rheumatoid factor, n (%) | 73/86 (85 %) | 133/155 (86 %) |
ACPA, n (%) | 67/71 (94 %) | 112/124 (90 %) |
C-reactive protein, median (range) | 14 (0.2–157) | 12 (0–179) |
Smoking, n (%) | 18 (9 %) | 49 (13 %) |